A team of scientists from Israel and the USA has recently examined the efficacy of coronavirus disease 2019 (COVID-19) vaccination in reducing the death risk among people aged 70 years and above. They observe that despite government-imparted relaxation on non-pharmaceutical control measures, the vaccine saved more lives than expected by individual-level vaccine efficacy.
A team of international scientists has recently identified a distinct set of proinflammatory mediators and metabolites associated with the fatal consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, they have established a link between gut microbiome alteration and hyper-inflammatory response in patients with severe COVID-19. The study is currently available on the […]
A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.
Researchers from the UK used EAVE II, an individual-level, national surveillance system, to determine the frequency of COVID-19-related fatalities among fully vaccinated individuals and to define the clinical and demographic characteristics of COVID-19 deaths in fully vaccinated individuals since the beginning of the COVID-19 vaccination program in Scotland.
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is one of the most important ways of fighting the ongoing COVID-19 pandemic, the recommendations for vaccination for pregnant and breastfeeding women are not consistent.
A new study posted to the medRxiv* preprint server, analyzed safety data from over 298 million mRNA COVID-19 vaccines administered in the first six months after the U.S. began its vaccination campaign.
Research published in the journal Nature Medicine suggests a risk for neurological complications after the first shot of a COVID-19 vaccine. However, the likelihood of developing neurological complications remains far greater among people infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).